A 3′-UTR polymorphism in soluble epoxide hydrolase gene is associated with acute rejection in renal transplant recipients

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Gervasini, Guillermo ^a   García Cerrada, Montserrat ^a   Coto, Eliecer ^b,f   Vergara, Esther ^c   García Pino, Guadalupe ^c   Alvarado, Raul ^c   Fernández Cavada, Maria Jesús ^c   Suárez Álvarez, Beatriz ^d   Barroso, Sergio ^c   Doblaré, Emilio ^c   Díaz Corte, Carmen ^e,f   López Larrea, Carlos ^e,f   Cubero, Juan Jose ^c  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HUCA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EPOXIDE HYDROLASE; 3' UNTRANSLATED REGION; EPHX2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ACUTE GRAFT REJECTION; ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EPHX2 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; DONOR; GENETICS; GRAFT REJECTION; MIDDLE AGED;

3' UNTRANSLATED REGIONS; EPOXIDE HYDROLASES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE DONORS;

EID: 84941946389     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133563     Document Type: Article

References (35)

1. Yang L, Maki-Petaja K, Cheriyan J, McEniery C, Wilkinson IB. The role of epoxyeicosatrienoic acids in the cardiovascular system. Br J Clin Pharmacol. 2015. doi: 10.1111/bcp.12603
2. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005; 289: F496-503. PMID: 16093425
3. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999; 285: 1276-1279. PMID: 10455056
4. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002; 82: 131-185. PMID: 11773611
5. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010; 24: 3770-3781. doi: 10.1096/fj.10-160119 PMID: 20495177
6. Sharma M, McCarthy ET, Reddy DS, Patel PK, Savin VJ, Medhora M, et al. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat. 2009; 89: 43-51. PMID: 19480064
7. Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ, et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke. 2002; 33: 1677-1684. PMID: 12053011
8. Fisslthaler B, Popp R, Michaelis UR, Kiss L, Fleming I, Busse R. Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase. Hypertension. 2001; 38: 1427-1432. PMID: 11751730
9. Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci U S A. 1994; 91: 7002-7006. PMID: 8041736
10. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol. 2003; 64: 482-490. PMID: 12869654
11. Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys. 2004; 427: 164-169. PMID: 15196990
12. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet. 2006; 15: 1640-1649. PMID: 16595607
13. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet. 2005; 14: 2829-2837. PMID: 16115816
14. Lee JP, Yang SH, Lee HY, Kim B, Cho JY, Paik JH, et al. Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney. PLoS One. 2012; 7: e37075. doi: 10.1371/journal. pone.0037075 PMID: 22590647
15. Lee JP, Yang SH, Kim DK, Lee H, Kim B, Cho JY, et al. In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy. Am J Physiol Renal Physiol. 2011; 300: F1283-1290. doi: 10.1152/ajprenal.00733.2010 PMID: 21429967
16. Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S, et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc. 2008; 40: 1353-1356. doi: 10.1016/j. transproceed.2008.03.137 PMID: 18589104
17. Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol. 2013; 69: 385-393. doi: 10.1007/s00228-012-1355-x PMID: 22886152
18. Gervasini G, Garcia M, Macias RM, Benitez J, Caravaca F, Cubero JJ. CYP2C8∗3 Polymorphism and Donor Age are Associated With Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors. J Clin Pharmacol. 2013; 53: 427-434. doi: 10.1002/jcph.15 PMID: 23426640
19. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int. 2012; 25: 471-480. doi: 10.1111/j.1432-2277.2012.01446.x PMID: 22369694
20. Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney International. 2005; 68: 1-13. PMID: 15954891
21. Levey AS, Greene T, Kuske J, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11: 155A.
22. Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005; 5: 1306-1311. PMID: 15888034
23. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22: 1928-1929. PMID: 16720584
24. Lebranchu Y, Baan C, Biancone L, Legendre C, Morales JM, Naesens M, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transplant International. 2014; 27: 129-138. doi: 10.1111/tri.12205 PMID: 24118550
25. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002; 74: 1486-1489. PMID: 12490779
26. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003; 76: 1233-1235. PMID: 14578760
27. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010; 49: 141-175. doi: 10.2165/11317350-000000000-00000 PMID: 20170205
28. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet. 2010; 49: 207-221. doi: 10.2165/11317550-000000000-00000 PMID: 20214406
29. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res. 2005; 68: 18-25. PMID: 15993870
30. Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol. 2012; 52: 319-328. doi: 10.1177/0091270010397049 PMID: 21422238
31. Podolin PL, Bolognese BJ, Foley JF, Long E 3rd, Peck B, Umbrecht S, et al. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013; 104-105: 25-31. doi: 10.1016/j.prostaglandins.2013.02.001 PMID: 23434473
32. Naderi GH, Mehraban D, Kazemeyni SM, Darvishi M, Latif AH. Living or deceased donor kidney transplantation: a comparison of results and survival rates among Iranian patients. Transplant Proc. 2009; 41: 2772-2774. doi: 10.1016/j.transproceed.2009.07.041 PMID: 19765431
33. Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, et al. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis. 2013; 227: 442-448. doi: 10.1016/j.atherosclerosis.2013.01.034 PMID: 23466098
34. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int. 2000; 57: 1100-1106. PMID: 10720962
35. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics. 2010; 26: 2474-2476. doi: 10.1093/bioinformatics/btq452 PMID: 20702402